– | Among approximately 3,000 patients followed over 3 years, the relative risk of mortality was 70% lower and the relative risk of hospitalization was 40% lower among patients treated in an HTC |
Celynda G. Tadlock, PharmD, MBA Vice President, Pharmacy Business Development Aetna |